Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the grant of 35,500 restricted stock units to four newly hired employees. The grants were approved by the company's Compensation Committee under the 2022 Inducement Plan.
The stock units, granted on September 2, 2025, will vest over a four-year period, with 25% vesting annually, contingent on continuous employment. This announcement is made in compliance with Nasdaq Listing Rule 5635(c)(4), which governs inducement grants for new employees.
Arcutis Biotherapeutics (Nasdaq: ARQT), societ脿 biofarmaceutica in fase commerciale specializzata in immuno-dermatologia, ha comunicato la concessione di 35.500 unit脿 azionarie vincolate a quattro nuovi dipendenti. Le assegnazioni sono state approvate dal Comitato per la Compensazione nell'ambito del 2022 Inducement Plan.
Le unit脿 azionarie, concesse il 2 settembre 2025, saranno soggette a un periodo di maturazione di quattro anni, con il 25% che matura ogni anno, subordinato alla continuit脿 del rapporto di lavoro. L'annuncio 猫 effettuato in conformit脿 alla Nasdaq Listing Rule 5635(c)(4), che disciplina le assegnazioni a titolo di incentivo per nuovi dipendenti.
Arcutis Biotherapeutics (Nasdaq: ARQT), una compa帽铆a biofarmac茅utica en fase comercial especializada en inmunodermatolog铆a, ha anunciado la concesi贸n de 35.500 unidades restringidas de acciones a cuatro empleados reci茅n contratados. Las concesiones fueron aprobadas por el Comit茅 de Compensaci贸n de la compa帽铆a en virtud del 2022 Inducement Plan.
Las unidades, otorgadas el 2 de septiembre de 2025, se consolidar谩n a lo largo de un per铆odo de cuatro a帽os, con un 25% que se consolida cada a帽o, condicionado a la continuidad del empleo. Este anuncio se realiza en cumplimiento de la Nasdaq Listing Rule 5635(c)(4), que regula las concesiones por incentivos a nuevos empleados.
Arcutis Biotherapeutics (Nasdaq: ARQT), 氅挫棴頂茧秬瓿� 攵勳暭毳� 鞝勲鞙茧 頃橂姅 靸侅梾 雼硠鞚� 氚旍澊鞓れ牅鞎巾殞靷澑 Arcutis臧� 雱� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 35,500臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 頃措嫻 攵�鞐姅 2022雲� 鞙犾澑 瓿勴殟(Inducement Plan)鞐� 霐半澕 須岇偓鞚� 氤挫儊鞙勳洂須� 鞀轨澑鞚� 韱淀暣 鞚措（鞏挫鞀惦媹雼�.
頃措嫻 欤检嫕 雼渼電� 2025雲� 9鞗� 2鞚�鞐� 攵�鞐悩鞐堨溂氅�, 4雲� 臧� 氩犾姢韺呺悩鞏� 毵る厔 25%鞌� 氩犾姢韺呺悩氅� 瓿勳啀 瓿犾毄霅橃柎 鞛堧姅 瓴届毎鞐愲 鞙犿毃頃╇媹雼�. 氤� 氚滍憸電� 鞁犾瀰 歆侅洂 雽�靸� 鞚胳劶韹半笇 攵�鞐ゼ 攴滌爼頃橂姅 Nasdaq 靸侅灔 攴滌箼 5635(c)(4)毳� 欷�靾橅晿鞐� 鞚措（鞏挫鞀惦媹雼�.
Arcutis Biotherapeutics (Nasdaq: ARQT), une soci茅t茅 biopharmaceutique en phase commerciale sp茅cialis茅e en immuno鈥慸ermatologie, a annonc茅 l'attribution de 35 500 unit茅s d'actions restreintes 脿 quatre nouveaux employ茅s. Les attributions ont 茅t茅 approuv茅es par le comit茅 de r茅mun茅ration de la soci茅t茅 dans le cadre du 2022 Inducement Plan.
Les unit茅s, attribu茅es le 2 septembre 2025, seront acquises sur une p茅riode de quatre ans, avec 25 % qui devient acquis chaque ann茅e, sous r茅serve de la continuit茅 de l'emploi. Cette annonce est faite conform茅ment 脿 la Nasdaq Listing Rule 5635(c)(4), qui encadre les attributions d'incitation pour les nouveaux employ茅s.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Immun鈥慏ermatologie spezialisiert hat, gab die Gew盲hrung von 35.500 Restricted Stock Units an vier neu eingestellte Mitarbeiter bekannt. Die Zuteilungen wurden vom Verg眉tungsausschuss des Unternehmens gem盲脽 dem 2022 Inducement Plan genehmigt.
Die am 2. September 2025 gew盲hrten Einheiten werden 眉ber einen Zeitraum von vier Jahren unverfallbar, wobei j盲hrlich 25 % unverfallbar werden, vorausgesetzt, das Arbeitsverh盲ltnis besteht fort. Diese Mitteilung erfolgt in 脺bereinstimmung mit der Nasdaq Listing Rule 5635(c)(4), die Anreizzuteilungen f眉r neue Mitarbeiter regelt.
- None.
- None.
WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- 听(狈补蝉诲补辩: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,500 restricted stock units of Arcutis鈥� common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis鈥� Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis鈥� unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit聽聽or follow Arcutis on , , and .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company鈥檚 current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the 鈥淩isk Factors鈥� section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
Investors
Brian Schoelkopf, Head of Investor Relations
FAQ
What type of stock compensation did Arcutis Biotherapeutics (ARQT) grant to new employees in September 2025?
What is the vesting schedule for ARQT's September 2025 restricted stock units?
How many new employees received Arcutis (ARQT) restricted stock units in September 2025?
When did Arcutis Biotherapeutics grant the inducement awards to new employees?
